Antipsychotics 4- Central nervous system depressants

Ginsenoside Rbj is a representative of the saponins derived from 20 (S )-proto-panaxadiol (Fig. 1). It exhibits central nervous system-depressant and antipsychotic... 

Ginsengoside Rbi (60) is a representative of the saponins derived from 20(5)-protopanaxadiol. It exhibits central nervous system-depressant and antipsychotic activity, protection against stress ulcer, increase of gastrointestinal motility and weak anti-inflammatory action. Rgi (61) -the major saponin of 20(5)-protopanaxatriol - shows weak CNS-stimulant action, antrfatigue activity and blood pressure activity [108,109] (O Scheme 25). 

Also note that the potential for an interaction between drugs does not preclude their concurrent use. Certain combinations are routinely prescribed without problems in many patients (as with lithium and antipsychotics), whereas others are contraindicated due to the severity of the interaction (for example, MAOIs and SSRIs). However, whenever psychiatric medications are coadministered, the additive potential of central nervous system depression and anticholinergic effects must be considered. 

Introduction During 1966, several new types of chemical structures were reported to have central nervous system depressant activity, and further studies were described of compounds previously classified in this area. The problem of defining further the type of activity to predict whether a given depressant will be of clinical application as an antipsychotic, anti-anxiety agent, sedative, hypnotic, anti-convulsant or anesthetic continues to occupy the attention of many investigators. 

Central nervous system depressants are medications that suppress the transmission of information throughout the central nervous system. There are seven broad classifications of central nervous system depressants. These are sedative-hypnotics, general and local anesthetics (discussed later in this chapter), analgesics, narcotic analgesics (Chapter 16), anticonvulsants, antipsychotics, and antidepressants (discussed later in this chapter)... 

Drugs and chemicals are known to cause activated interaction. The depressant action of opioid drugs is enhanced by drugs acting on the central nervous system (CNS) such as alcohol, anesthetics, anxiolytics, hypnotics, tricyclic antidepressants, and antipsychotics. Concomitant administration of opioid analgesics and monoamine oxidase inhibitors (MAOIs) should be avoided, or extra care should be taken if such a therapy is inevitable. Fatal reactions are reported when treated along with selegiline. Interactions also are reported with cyclizine, cimetidine, mexiletine, cisapride, metoclopramide, or domperidone. 

Neuroleptic. A drug producing symptoms similar to those of depressant diseases of the central nervous system (CNS). Frequently used to refer to an antipsychotic agent. 

Central nervous system (CNS) depressants such e alcohol, narcotic analgeie, tricyclic antidepresants (see Cliap. 31), and the antipsychotic dru (see (Dli i. 32), increase the sedative effects of the antianxiety dru. Combination of any of th se dru with the antianxiely dni is dangerous and can cause serious respiratory depression and profound sedation. Ingestion of alcohol with the antianxiely dru can cause convulsions and coma... 

There are seven broad classifications of medications that depress the central nervous system. These are sedative-hypnotics, general and local anesthetics, analgesics, narcotic analgesics, anticonvulsants, antipsychotics, and antidepressants. 

Uses in the treatment of schizophrenia anti-emetic as an antipsychotic in pills, injections, and suppositories to relieve nausea and vomiting associated with malignant diseases. In veterinary medicine, it is used as an anti-emetic, tranquilizer and sedative. It has slight antihistaminic and antiadrenaline actions. It is a peripheral vasodilator and a depressant that blocks dopamine receptors in the central nervous system... 

---